Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01776307 · ClinicalTrials.gov registry record · Phase 2
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT01776307 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 200 participants.
The verdict
NCT01776307, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is an open label, multi-center, Phase 2 study of BBI608 in combination with cetuximab, panitumumab or capecitabine in patients with advanced colorectal cancer.
Interventions
- DRUG Capecitabine
- DRUG Cetuximab
- DRUG Panitumumab
- DRUG BBI608
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2012-03 |
| Est. Completion | 2020-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01776307
The ClinicalTrials.gov registry entry for NCT01776307 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Capecitabine is the first listed.
NCT01776307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01776307 about?
NCT01776307 is a clinical study titled "A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer". This is an open label, multi-center, Phase 2 study of BBI608 in combination with cetuximab, panitumumab or capecitabine in patients with advanced colorectal cancer.
What is the current status of trial NCT01776307?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2012-03. Estimated completion is 2020-04.
What interventions are being tested in trial NCT01776307?
The interventions under investigation include: Capecitabine (DRUG), Cetuximab (DRUG), Panitumumab (DRUG), BBI608 (DRUG).
Who is sponsoring clinical trial NCT01776307?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.